SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care in India BOSTON and ROLLE, Switzerland, Jan. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Karkinos Healthcare, a purpose-driven cancer care technology network based in India, will partner with SOPHiA ...

Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology, Dasa and The Royal Marsden announced today BOSTON and ROLLE, Switzerland, Jan. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, will share an overview of its near-term growth strategy, fueled by strong adoption and opportunity for the SOPHiA ...

Insights from multimodal datasets on the platform fuel cancer research in Canada BOSTON and ROLLE, Switzerland, Jan. 8, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced a collaboration with Exactis Innovation, based in Montreal, Quebec, who will contribute to cancer research and data-driven decision-making through SOPHiA GENETICS' multimodal real-world data offering. Exactis Innovation is a non-profit network of hospit ...

The Hospital will use SOPHiA GENETICS technology to streamline workflows and expedite research BOSTON and ROLLE, Switzerland, Dec. 21, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2023 Results Conference Call November 7, 2023 8:00 AM ET Company Participants Katherine Bailon - Head, IR Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO and COO Conference Call Participants Yuko Oku - Morgan Stanley Kyle Boucher - TD Cowen Mark Massaro - BTIG Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS Third Quarter ...

Exhibit 99.1 Table of Contents SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements F-2 Table of Contents SOPHiA GENETICS SA, Rolle Interim Condensed Consolidated Statements of Loss (Amounts in USD thousands, except per share data) (Unaudited) | | | | | Three months ended | | | | Nine months ended | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | September 30, | | | | September 30, | | | | Notes | | 2023 | | 2022 | | 2023 | | 2022 | | Revenue | 5 | $ | 1 ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Katherine Bailon - Head, Investor Relations Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - Chief Financial Officer and COO Conference Call Participants Edmund Tu - Morgan Stanley Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Vidyun Bais - BTIG Operator Hello, ladies and gentlemen. And thank you for joining SOPHiA GENETICS Second Quarter 2020 Earnings Call. Our host for today is Katherin ...

Table of Contents | | Unaudited Interim Condensed Consolidated Financial Statements | F-2 | | --- | --- | --- | | – | Unaudited Interim Condensed Consolidated Statements of Loss | F-3 | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss | F-4 | | – | Unaudited Interim Condensed Consolidated Balance Sheets | F-5 | | – | Unaudited Interim Condensed Consolidated Statements of Changes in Equity | F-6 | | – | Unaudited Interim Condensed Consolidated Statements of Cash Flows | F-8 | | ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Katherine Bailon - Vice President of Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - Chief Financial Officer and Chief Operating Officer Conference Call Participants Tejas Savant - Morgan Stanley Marta Nazarovets - JPMorgan Chase & Co. Kyle Boucher - TD Cowen Operator Good morning, and welcome to the SOPHiA GENETICS' First Quarter 2023 Earnings Conference Call ...

Revenue and Profitability - Revenue for Q1 2023 was $13,966 thousand, a 28.9% increase from $10,861 thousand in Q1 2022[5] - Gross profit for the period was $9,694 thousand, compared to $6,710 thousand in the same period last year, reflecting a 44.5% increase[5] - Revenue from the SOPHiA DDM Platform was $13.749 million, up from $10.431 million, indicating a growth of 31.5% year-over-year[36] - Total revenue for the three months ended March 31, 2023, was $13.966 million, representing a 28.9% increase from $10.861 million in the same period of 2022[35] Loss and Financial Performance - Operating loss decreased to $19,287 thousand in Q1 2023 from $25,021 thousand in Q1 2022, representing a 22.0% improvement[5] - Loss for the period was $19,700 thousand, down from $25,487 thousand in Q1 2022, indicating a 22.8% reduction[7] - The net loss attributed to shareholders for the three months ended March 31, 2023, was $19.700 million, an improvement from a net loss of $25.487 million in the same period of 2022[41] - Total comprehensive loss for Q1 2023 was $17,799 thousand, compared to $27,020 thousand in Q1 2022, a decrease of 34.2%[7] Cash Flow and Assets - Cash and cash equivalents at the end of Q1 2023 were $160,762 thousand, slightly down from $161,305 thousand at the end of 2022[10] - Total assets decreased to $232,058 thousand as of March 31, 2023, from $243,838 thousand at the end of 2022[10] - Accounts receivable increased to $7.696 million as of March 31, 2023, compared to $6.060 million as of December 31, 2022, reflecting a 26.9% rise[40] - The Company had no borrowings outstanding under its credit facility as of March 31, 2023[43] Shareholder Information - The company reported a basic and diluted loss per share of $0.31 for Q1 2023, an improvement from $0.40 in Q1 2022[5] - The weighted average number of shares in issue increased to 64,242,871 as of March 31, 2023, compared to 63,891,630 in the prior year[41] - The Company held 2,072,700 treasury shares as of March 31, 2023, down from 2,483,000 shares held as of March 31, 2022[30] Compensation and Expenses - Share-based compensation expense totaled $2.430 million for the three months ended March 31, 2023, compared to $3.471 million in the same period of 2022, indicating a decrease of 30%[44] - Total compensation for key management and non-executive directors decreased to $2,439,000 in Q1 2023 from $2,520,000 in Q1 2022, a decline of approximately 3.2%[47] - Share-based compensation expense reduced to $1,720,000 in Q1 2023 from $1,900,000 in Q1 2022, representing a decrease of about 9.5%[47] - Salaries and other short-term employee benefits slightly decreased to $551,000 in Q1 2023 compared to $553,000 in Q1 2022, a decline of approximately 0.4%[47] - Pension costs increased to $52,000 in Q1 2023 from $50,000 in Q1 2022, reflecting a growth of 4%[47] - Other compensation rose significantly to $116,000 in Q1 2023 from $17,000 in Q1 2022, marking an increase of approximately 582.4%[47] Other Information - The Company operates in a single operating segment, with financial performance assessed as such by senior management[34] - There were no material subsequent events reported after the reporting date[48]